Canagliflozin ameliorates aortic and hepatic dysfunction in dietary-induced hypercholesterolemia in the rabbit.

Abstract

AIMS:

Canagliflozin is an antidiabetic agent which lowers blood glucose levels by inhibiting the glucose reabsorption machinery in the proximal tubules. There have not been conducted any study on its direct impact on hypercholesterolemia and associated vascular disorders independently of blood glucose lowering activity.

MATERIALS AND METHODS:

Rabbits were arranged in 3 groups: Group 1 (Control): regular rabbit chow; Group 2 (HCD): 1% cholesterol-enriched chow was given to rabbits for 4 weeks; Group 3 (HCD-CANA): 1% cholesterol-enriched chow was fed to rabbits concurrently with canagliflozin (10 mg/kg/day, orally) for 4 weeks. At the end of experiment, blood and tissue samples were obtained for biochemical, histological, immunohistochemical, and vascular reactivity assessment.

KEY FINDINGS:

When statistically compared to Control (P < 0.05), HCD showed a significant increase in the serum triglycerides, low-density lipoprotein, total cholesterol, C-reactive protein, alkaline phosphatase, alanine aminotransferase and aspartate aminotransferase. Furthermore, a significant decrease was seen in both liver and aortic levels of glutathione peroxidase and superoxide dismutase concurrently with a significant elevation in malondialdehyde levels. Aortic levels of nitrate/nitrite ratio were significantly elevated. Acetylcholine-induced relaxation was impaired as the Emax decreased significantly in aortae. Moreover, a significant increase was seen in the level of aortic intima/media ratio. Canagliflozin treatment significantly improved vascular function, lipid profile and inflammation and reduced liver injury.

SIGNIFICANCE:

Our data suggest that SGLT-2 inhibition via canagliflozin not only possesses an antihyperglycemic activity, but also improves hypercholesterolemia, vascular and liver function in dietary-induced hypercholesterolemia in the rabbit.

• Authors: Nora A Ashry, Rania R Abdelaziz, Ghada M Suddek, Mohamed A Saleh
• Journal: Life sciences (Life Sci) Vol. 280 Pg. 119731 (09 01 2021) ISSN: 1879-0631 [Electronic] Netherlands
• PMID: 34144054 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Chemical References

• Cholesterol, Dietary
• Hypoglycemic Agents
• Lipids
• Sodium-Glucose Transporter 2 Inhibitors
• Canagliflozin

Topics

• Animals
• Aorta (drug effects, physiopathology)
• Canagliflozin (therapeutic use)
• Cholesterol, Dietary (adverse effects)
• Hypercholesterolemia (blood, drug therapy, etiology, physiopathology)
• Hypoglycemic Agents (therapeutic use)
• Lipids (blood)
• Liver (drug effects, physiopathology)
• Male
• Rabbits
• Sodium-Glucose Transporter 2 Inhibitors (therapeutic use)